Nicolas Veziris

List of Publications by Year
in descending order

123 papers	4,836 citations	109321 35 h-index	106344 65 g-index
152 all docs	152 docs citations	152 times ranked	4425 citing authors

#	Article	IF	Citations
1	Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. Journal of Infection, 2022, 84, 834-872.	3.3	8
2	Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015â€“2020). Respiration, 2022, 101, 367-375.	2.6	5
3	Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal, 2022, 59, 2200166.	6.7	15
4	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59, 2200388.	6.7	15
5	Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms, 2022, 10, 1215.	3.6	0
6	How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms, 2022, 10, 1436.	3.6	3
7	Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal, 2021, 58, 2100641.	6.7	5
8	Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal, 2021, 57, 2004315.	6.7	0
9	Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research, 2021, 79, 100825.	0.6	2
10	Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases, 2021, 107, 86-91.	3.3	11
11	Revisiting Species Identification within the Enterobacter cloacae Complex by Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry. Microbiology Spectrum, 2021, 9, e0066121.	3.0	17
12	Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region. American Journal of Tropical Medicine and Hygiene, 2021, 104, 223-228.	1.4	3
13	Non-tuberculous mycobacterial pulmonary diseases in France: an 8Âyears nationwide study. BMC Infectious Diseases, 2021, 21, 1165.	2.9	8
14	Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. Emerging Infectious Diseases, 2020, 26, 1792-1800.	4.3	30
15	Bedaquiline and delamanid for drug-resistant tuberculosis: a clinicianâ€™s perspective. Future Microbiology, 2020, 15, 779-799.	2.0	11
16	Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 2020, 14, e0007857.	3.0	10
17	Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing. Frontiers in Microbiology, 2020, 11, 81.	3.5	9
18	Fully weekly antituberculosis regimen: a proof-of-concept study. European Respiratory Journal, 2020, 56, 1902502.	6.7	3

#	Article	IF	Citations
19	An expert statment on clinical considerations before treating NTM lung infection. , 2020, , .		0
20	Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1072-1073.	5.6	2
21	Mycobacterium bolletii Lung Disease inÂCystic Fibrosis. Chest, 2019, 156, 247-254.	0.8	9
22	Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 936-943.	4.3	68
23	Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2019, 23, 99-104.	1.2	10
24	Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. International Journal of Tuberculosis and Lung Disease, 2019, 23, 1050-1054.	1.2	10
25	Bacillus Calmette-Guerin infection following intravesical instillation: Does the strain matter?. MÃ©decine Et Maladies Infectieuses, 2019, 49, 350-355.	5.0	2
26	Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. Clinical Infectious Diseases, 2019, 68, 1410-1411.	5.8	2
27	National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey. , 2019, , .		3
28	Safety and efficacy of exposure to bedaquilineâ”delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. European Respiratory Journal, 2018, 51, 1702550.	6.7	30
29	Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. Pulmonology, 2018, 24, 132-141.	2.1	19
30	Comparison of methods available for identification of Mycobacterium chimaera. Clinical Microbiology and Infection, 2018, 24, 409-413.	6.0	34
31	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
32	Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	24
33	Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. International Journal of Tuberculosis and Lung Disease, 2018, 22, 54-59.	1.2	12
34	Estimation of pyrazinamidase activity using a cell-free In vitro synthesis of pnca and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. International Journal of Mycobacteriology, 2018, 7, 16.	0.6	6
35	Multidrug and extensively drug-resistant tuberculosis. MÃ©decine Et Maladies Infectieuses, 2017, 47, 3-10.	5.0	26
36	Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. European Respiratory Journal, 2017, 49, 1601719.	6.7	86

#	Article	IF	Citations
37	Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601799.	6.7	112
38	Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosi s in France. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
39	Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. MÃ©decine Et Maladies Infectieuses, 2017, 47, 340-348.	5.0	11
40	Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?. Journal of Antimicrobial Chemotherapy, 2017, 72, 2326-2333.	3.0	24
41	Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. International Journal of Tuberculosis and Lung Disease, 2017, 21, 167-174.	1.2	34
42	Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. Journal of Antimicrobial Chemotherapy, 2017, 72, 1669-1677.	3.0	44
43	Should single antibiotic therapy be avoided for nontuberculous mycobacteria?. MÃ©decine Et Maladies Infectieuses, 2017, 47, 566-568.	5.0	1
44	Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. European Respiratory Journal, 2017, 50, 1700891.	6.7	3
45	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1489-1490.	5.6	2
46	Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	52
47	Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. Emerging Infectious Diseases, 2017, 23, 1731-1732.	4.3	23
48	Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009â€“2014. Emerging Infectious Diseases, 2016, 22, 518-521.	4.3	10
49	Description of compensatorygyrAmutations restoring fluoroquinolone susceptibility inMycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 2428-2431.	3.0	9
50	Performance of the New Version (v2.0) of the GenoType MTBDR sl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. Journal of Clinical Microbiology, 2016, 54, 1573-1580.	3.9	46
51	Rifabutin: where do we stand in 2016?. Journal of Antimicrobial Chemotherapy, 2016, 71, 1759-1771.	3.0	61
52	Standardized interpretation of antibiotic susceptibility testing and resistance genotyping forMycobacterium abscessuswith regard to subspecies anderm41sequevar. Journal of Antimicrobial Chemotherapy, 2016, 71, 2208-2212.	3.0	54
53	In vivo Mycobacterium tuberculosisfluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. Journal of Antimicrobial Chemotherapy, 2016, 71, 3465-3472.	3.0	9
54	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1029-1031.	5.6	71

#	Article	IF	Citations
55	Infections caused byMycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Review of Anti-Infective Therapy, 2016, 14, 1139-1154.	4.4	63
56	Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. European Respiratory Journal, 2016, 48, 582-585.	6.7	19
57	Induction therapy with linezolid/clarithromycin combination for <scp>M</scp>ycobacterium chelonae skin infections in immunocompromised hosts. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 101-105.	2.4	6
58	XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. MÃ©decine Et Maladies Infectieuses, 2016, 46, 52-55.	5.0	11
59	Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infectious Diseases, The, 2016, 16, 294.	9.1	43
60	Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 783-793.	3.0	2
61	Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0005066.	3.0	23
62	Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 4800-4808.	3.2	51
63	Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis, 2015, 14, 594-599.	0.7	37
64	Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?. Open Forum Infectious Diseases, 2015, 2, ofv175.	0.9	4
65	Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1519-1524.	3.2	35
66	Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and theinhAPromoter (â˜’15Câ†’T). Journal of Clinical Microbiology, 2015, 53, 3104-3104.	3.9	2
67	Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. Clinical Microbiology and Infection, 2015, 21, 472.e7-472.e10.	6.0	5
68	Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy, 2015, 59, 7153-7155.	3.2	10
69	Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 63-69.	0.7	80
70	Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clinical Infectious Diseases, 2015, 60, 188-194.	5.8	165
71	Concomitant Multidrug-resistant Pulmonary Tuberculosis and Susceptible Tuberculous Meningitis. Emerging Infectious Diseases, 2014, 20, 506-507.	4.3	3
72	Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare. Journal of Clinical Microbiology, 2014, 52, 4439-4440.	3.9	15

#	Article	IF	Citations
73	French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPASÂ® in MDR-TB Patients. Chemotherapy, 2014, 60, 174-179.	1.6	3
74	Comparison of a Semiautomated Commercial Repetitive-Sequence-Based PCR Method with Spoligotyping, 24-Locus Mycobacterial Interspersed Repetitive-Unit-Variable-Number Tandem-Repeat Typing, and Restriction Fragment Length Polymorphism-Based Analysis of IS6110 for Mycobacterium tuberculosis Typing. Journal of Clinical Microbiology, 2014, 52, 4082-4086.	3.9	9
75	Rifampicin mono-resistant tuberculosis in France: a 2005â€“2010 retrospective cohort analysis. BMC Infectious Diseases, 2014, 14, 18.	2.9	22
76	Clonal Relationship and Differentiation among Mycobacterium abscessus Isolates as Determined Using the Semiautomated Repetitive Extragenic Palindromic Sequence PCR-Based DiversiLab System. Journal of Clinical Microbiology, 2014, 52, 1969-1977.	3.9	11
77	In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus. Journal of Infectious Diseases, 2014, 209, 905-912.	4.0	89
78	Mycobacterial infection of breast prosthesis â€“ a conservative treatment: a case report. BMC Infectious Diseases, 2014, 14, 238.	2.9	13
79	First Whole-Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium bovis BCG. Genome Announcements, 2014, 2, .	0.8	0
80	Cavitary pulmonary disease in a patient treated with natalizumab. Presse Medicale, 2014, 43, 1009-1012.	1.9	7
81	Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. PLoS ONE, 2014, 9, e101434.	2.5	20
82	Les nouveaux antituberculeux (1)Â: nouvelles utilisations de molÃ©cules existantes. Journal Des Anti-infectieux, 2013, 15, 95-101.	0.1	2
83	Voluminous pseudotumor due to Mycobacterium malmoense. Presse Medicale, 2013, 42, 227-230.	1.9	1
84	In vivo selection of a multidrug-resistant <I>Mycobacterium avium</I> isolate in a patient with AIDS [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 141-142.	1.2	1
85	Resistance of M. leprae to Quinolones: A Question of Relativity?. PLoS Neglected Tropical Diseases, 2013, 7, e2559.	3.0	11
86	Evaluation of the Fluo-RAL Module for Detection of Tuberculous and Nontuberculous Acid-Fast Bacilli by Fluorescence Microscopy. Journal of Clinical Microbiology, 2013, 51, 3469-3470.	3.9	4
87	Impact of Fluoroquinolone Resistance on Bactericidal and Sterilizing Activity of a Moxifloxacin-Containing Regimen in Murine Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4496-4500.	3.2	20
88	A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Eurosurveillance, 2013, 18, 20555.	7.0	37
89	Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M. tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 1990-1996.	3.2	65
90	Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris. International Journal of Tuberculosis and Lung Disease, 2012, 16, 649-655.	1.2	17

#	Article	IF	Citations
91	Performance of QuantiferonÂ® for the diagnosis TB. MÃ©decine Et Maladies Infectieuses, 2012, 42, 579-584.	5.0	2
92	Osteomyelitis of the wrist caused by Mycobacterium arupense in an immunocompetent patient: a unique case. International Journal of Infectious Diseases, 2012, 16, e761-e762.	3.3	14
93	Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient. Journal of Medical Microbiology, 2012, 61, 1617-1620.	1.8	7
94	Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France. Journal of Infection, 2012, 64, 589-595.	3.3	9
95	Electronic Sensors for Assessing Interactions between Healthcare Workers and Patients under Airborne Precautions. PLoS ONE, 2012, 7, e37893.	2.5	40
96	Relapsing Mycobacterium Genavense Infection as a Cause of Late Death in a Lung Transplant Recipient: Case Report and Review of the Literature. Experimental and Clinical Transplantation, 2012, 10, 618-620.	0.5	16
97	Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based Single Nucleotide Polymorphism Genotyping Assay Using iPLEX Gold Technology for Identification of Mycobacterium tuberculosis Complex Species and Lineages. Journal of Clinical Microbiology, 2011, 49, 3292-3299.	3.9	35
98	Activity of Carbapenems Combined with Clavulanate against Murine Tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 2597-2600.	3.2	51
99	Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl Sequencing. Antimicrobial Agents and Chemotherapy, 2011, 55, 775-781.	3.2	291
100	Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 355-360.	3.2	80
101	Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis. PLoS ONE, 2011, 6, e17556.	2.5	60
102	Rapid Identification of Mycobacterial Whole Cells in Solid and Liquid Culture Media by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. Journal of Clinical Microbiology, 2010, 48, 4481-4486.	3.9	151
103	Detection by GenoType MTBDR sl Test of Complex Mechanisms of Resistance to Second-Line Drugs and Ethambutol in Multidrug-Resistant Mycobacterium tuberculosis Complex Isolates. Journal of Clinical Microbiology, 2010, 48, 1683-1689.	3.9	170
104	Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 4765-4771.	3.2	70
105	Identification and Genotyping of Mycobacterium tuberculosis Complex Species by Use of a SNaPshot Minisequencing-Based Assay. Journal of Clinical Microbiology, 2010, 48, 1758-1766.	3.9	42
106	Daptomycin is not active against rapidly growing mycobacteria. Journal of Medical Microbiology, 2010, 59, 135-136.	1.8	8
107	Sterilizing Activity of R207910 (TMC207)-containing Regimens in the Murine Model of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 553-557.	5.6	74
108	A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 75-79.	5.6	63

#	Article	IF	Citations
109	Retrospective review of Pneumocystis jirovecii pneumonia in a French intensive care unit (1994â€“2000). International Journal of STD and AIDS, 2009, 20, 441-442.	1.1	2
110	Cutaneous miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review. Clinical and Experimental Dermatology, 2009, 34, e690-e692.	1.3	11
111	Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. International Journal of Tuberculosis and Lung Disease, 2009, 13, 260-5.	1.2	31
112	The Peptidoglycan of Stationary-Phase Mycobacterium tuberculosis Predominantly Contains Cross-Links Generated by <scp>l,d</scp> -Transpeptidation. Journal of Bacteriology, 2008, 190, 4360-4366.	2.2	300
113	Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004. Epidemiology and Infection, 2008, 136, 1172-1178.	2.1	2
114	Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis. Antimicrobial Agents and Chemotherapy, 2007, 51, 1011-1015.	3.2	160
115	Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 423-425.	2.9	23
116	Performance of the Genotype MTBDR Line Probe Assay for Detection of Resistance to Rifampin and Isoniazid in Strains of Mycobacterium tuberculosis with Low- and High-Level Resistance. Journal of Clinical Microbiology, 2006, 44, 3659-3664.	3.9	116
117	Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. Antimicrobial Agents and Chemotherapy, 2006, 50, 3543-3547.	3.2	127
118	Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis : Functional Analysis of Mutant Enzymes. Antimicrobial Agents and Chemotherapy, 2006, 50, 104-112.	3.2	176
119	Functional Analysis of DNA Gyrase Mutant Enzymes Carrying Mutations at Position 88 in the A Subunit Found in Clinical Strains of Mycobacterium tuberculosis Resistant to Fluoroquinolones. Antimicrobial Agents and Chemotherapy, 2006, 50, 4170-4173.	3.2	45
120	Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. Antimicrobial Agents and Chemotherapy, 2005, 49, 4015-4019.	3.2	18
121	Fluoroquinolone-Containing Third-Line Regimen against Mycobacterium tuberculosis In Vivo. Antimicrobial Agents and Chemotherapy, 2003, 47, 3117-3122.	3.2	75
122	Good Interpretation of the Results of a Diagnostic Test. Clinical Infectious Diseases, 2003, 37, 1143-1143.	5.8	2
123	Empyema of the thorax due to Gemella haemolysans. Journal of Infection, 1999, 39, 245-246.	3.3	13